Cannabinoid Encyclopedia

Cannabinoid guide

What is OEA?

A clear guide to OEA: what it is, what researchers have studied, how strong the evidence is, and what to know about safety.

Updated July 2026 15 research sources Mostly early-stage research

The short answer

OEA, in simple terms

OEA is a cannabinoid-related compound represented in the scientific literature. Researchers study it for possible effects, safety, and how it works in the body. Most of the current evidence is preclinical or focused on biological mechanisms. The evidence does not turn this into one proven benefit, because studies can use different products, doses, routes, people, and outcomes. 1

Choose your next step

Want the quick path or the full picture?

Use this guide the way you need to. Start with the practical question, then open the study detail only when it helps answer something about OEA.

Why people look into itSee the main questions before the research details. What researchers studiedSee the main areas and the evidence behind each one. Safety and limitsKeep product, dose, medications, and context in view. Open the sourcesGo directly to the studies and references used here.

Why people look into OEA

What OEA is commonly talked about for

These cards show the questions most represented in this source set. They are not a list of proven benefits, and the evidence label matters as much as the topic name.

  1. Too limited for a firm answer

    TRPV1

    Researchers have examined OEA in connection with TRPV1. The source details determine whether that is a human finding, an early model, or an open question. 3

    See research areas

  2. Mostly mechanism-focused

    OEA biology, receptor pharmacology, feeding, metabolism, physiology, or safety-relevant mechanisms

    Safety research asks how OEA, its dose, route, formulation, and other medications may change risk. The available evidence may not answer the safety question for every product or person. 2

    See research areas

Bottom line: Start with the exact question you care about, then check the study type, product, dose, and outcome before treating a research signal as a real-world effect.

Key takeaways

What to know first

  1. 1

    Research on OEA covers OEA biology, receptor pharmacology, feeding, metabolism, physiology, or safety-relevant mechanisms and TRPV1; those areas should not be combined into one claim. 1

  2. 2

    Most of the current evidence is preclinical or focused on biological mechanisms. 2

  3. 3

    Dose, formulation, route, study population, and outcome can change how closely a study applies to a real-world question. 3

Research areas

What has OEA been studied for?

These are the main questions represented in the current literature. Each link opens a source used to build the overview.

Mostly mechanism-focused

OEA biology, receptor pharmacology, feeding, metabolism, physiology, or safety-relevant mechanisms

Researchers have examined OEA in connection with OEA biology, receptor pharmacology, feeding, metabolism, physiology, or safety-relevant mechanisms. The studies may differ in compound, formulation, dose, route, population, and outcome. 2

Too limited for a firm answer

TRPV1

Studies connect OEA with TRPV1 at the level of receptors, enzymes, signaling, or pharmacology. This helps explain how the biology might work, but it does not prove a health outcome. 3

How strong is the research?

Not every study answers the same question

This page separates research in people, research reviews, and earlier-stage biology before interpreting the larger question.

2 sources

Human studies

Research involving people is closest to everyday health questions. The product, dose, population, and outcome still determine what each study can show.

10 sources

Reviews and evidence summaries

Reviews can compare several studies at once. Their conclusion is only as strong and as relevant as the studies they include.

3 sources

Lab, animal, and mechanism research

Early-stage research can explain biological interest. It cannot, by itself, show that the same effect happens in people.

What these studies actually looked at

The research on OEA is not one kind of study. This source set includes 10 narrative or expert reviews, 3 animal studies, 1 cell or laboratory study, and 1 clinical study in people. 3

The recorded populations or models include animal models (4 sources), people or patients (2 sources), and cells or tissue models (1 source). A result from one group or model should not be assumed to apply to another. 4

The most common recorded outcome focus is oEA biology, receptor pharmacology, feeding, metabolism, physiology, or safety-relevant mechanisms (14 sources) and tRPV1 channel activity, desensitization, binding, signaling, or pharmacology (1 source). Closely related outcome names can still describe different measurements. 5

The OEA source set also contains findings or reviews that remain too limited, indirect, or mixed for a broad answer. That uncertainty is part of the result, not an empty space to fill with assumptions. 6

Examples from the literature

What did the studies actually look at?

Each example names the research question and the study details recorded for that source.

animal study

Analgesic properties of oleoylethanolamide (OEA) in visceral and inflammatory pain.

On this page, this source examines OEA and oEA biology, receptor pharmacology, feeding, metabolism, physiology, or safety-relevant mechanisms. 1

Study type
animal study
Population or model
animal models
Outcome focus
oEA biology, receptor pharmacology, feeding, metabolism, physiology, or safety-relevant mechanisms
Evidence stage
mechanism-focused research

narrative or expert review

Endocannabinoids and nutrition.

On this page, this source examines OEA and oEA biology, receptor pharmacology, feeding, metabolism, physiology, or safety-relevant mechanisms. 2

Study type
narrative or expert review
Population or model
people or patients
Outcome focus
oEA biology, receptor pharmacology, feeding, metabolism, physiology, or safety-relevant mechanisms
Evidence stage
evidence still limited

narrative or expert review

Novel cannabinoid receptors.

On this page, this source examines OEA activity involving TRPV1. 3

Study type
narrative or expert review
Population or model
animal models
Outcome focus
tRPV1 channel activity, desensitization, binding, signaling, or pharmacology
Evidence stage
evidence still limited

clinical study in people

Investigation the effect of oleoylethanolamide supplementation on the abundance of Akkermansia muciniphila bacterium and the dietary intakes in people with obesity: A randomized clinical trial.

On this page, this source examines OEA and oEA biology, receptor pharmacology, feeding, metabolism, physiology, or safety-relevant mechanisms. 4

Study type
clinical study in people
Outcome focus
oEA biology, receptor pharmacology, feeding, metabolism, physiology, or safety-relevant mechanisms
Evidence stage
evidence still limited

narrative or expert review

A fatty gut feeling.

On this page, this source examines OEA and oEA biology, receptor pharmacology, feeding, metabolism, physiology, or safety-relevant mechanisms. 5

Study type
narrative or expert review
Outcome focus
oEA biology, receptor pharmacology, feeding, metabolism, physiology, or safety-relevant mechanisms
Evidence stage
evidence still limited

Safety and limits

What should readers keep in mind?

Research on OEA should be read beside safety. A compound can be non-intoxicating or naturally occurring and still have pharmacologic effects, side effects, interactions, or product-quality concerns. 2

Research doses are descriptions of what a study tested. They are not personal dosing instructions. Questions involving medications, pregnancy, children, driving, liver health, heart health, or serious symptoms deserve professional medical guidance.

Drug interactions Pregnancy and children Driving and impairment All safety topics

Common questions

Questions people ask

What is OEA?

OEA is a cannabinoid-related compound studied across OEA biology, receptor pharmacology, feeding, metabolism, physiology, or safety-relevant mechanisms and TRPV1. This page separates those research questions so they are not mistaken for one broad claim. 7

What has OEA been studied for?

The current source set includes OEA biology, receptor pharmacology, feeding, metabolism, physiology, or safety-relevant mechanisms and TRPV1. Each area may use different doses, products, routes, populations, and outcome measures. 8

How strong is the research on OEA?

Most of the current evidence is preclinical or focused on biological mechanisms. 9

Is OEA safe?

Safety cannot be answered for OEA without context. Dose, route, formulation, medications, and the person using it can all change risk. 10

Sources

Read the research

The numbered sources below support the main overview. Links open the PubMed record or DOI in a new tab.

  1. 1
    Analgesic properties of oleoylethanolamide (OEA) in visceral and inflammatory pain. animal study; mechanism-focused research PubMed 17449181 DOI 10.1016/j.pain.2007.03.008
  2. 2
    Endocannabinoids and nutrition. narrative or expert review; evidence still limited PubMed 18426507 DOI 10.1111/j.1365-2826.2008.01687.x
  3. 3
    Novel cannabinoid receptors. narrative or expert review; evidence still limited PubMed 17906678 DOI 10.1038/sj.bjp.0707481
  4. 4
    Investigation the effect of oleoylethanolamide supplementation on the abundance of Akkermansia muciniphila bacterium and the dietary intakes in people with obesity: A randomized clinical trial. clinical study in people; evidence still limited PubMed 31132422 DOI 10.1016/j.appet.2019.05.032
  5. 5
    A fatty gut feeling. narrative or expert review; evidence still limited PubMed 23567058 DOI 10.1016/j.tem.2013.03.001
  6. 6
    Brain molecules and appetite: the case of oleoylethanolamide. narrative or expert review; evidence still limited PubMed 23464987 DOI 10.2174/1871524911313010010
  7. 7
    N-acylethanolamines, anandamide and food intake. narrative or expert review; evidence still limited PubMed 19413995 DOI 10.1016/j.bcp.2009.04.024
  8. 8
    Oleoylethanolamide: A novel pharmaceutical agent in the management of obesity-an updated review. narrative or expert review; evidence still limited PubMed 30537148 DOI 10.1002/jcp.27913
  9. 9
    Regulation of Cholesterol and Triglyceride Metabolism by Fatty acid Ethanolamides. narrative or expert review; evidence still limited PubMed 42068417 DOI 10.1007/s11883-026-01417-z
  10. 10
    Regulation of food intake by oleoylethanolamide. narrative or expert review; evidence still limited PubMed 15770421 DOI 10.1007/s00018-004-4494-0
  11. 11
    Role of acylethanolamides in the gastrointestinal tract with special reference to food intake and energy balance. narrative or expert review; evidence still limited PubMed 19285259 DOI 10.1016/j.beem.2008.10.003
  12. 12
    The endocannabinoid and paracannabinoid systems in natural reward processes: possible pharmacological targets? narrative or expert review; evidence still limited PubMed 40274041 DOI 10.1016/j.physbeh.2025.114929
See all 15 research sources

This complete source list is the deeper research layer for the page. Study type and evidence context are shown when they are available in the current record.

  1. Novel cannabinoid receptors. narrative or expert review; evidence still limited / 1 linked research note PubMed 17906678
  2. Endocannabinoids and nutrition. narrative or expert review; evidence still limited / 1 linked research note PubMed 18426507
  3. N-acylethanolamines, anandamide and food intake. narrative or expert review; evidence still limited / 1 linked research note PubMed 19413995
  4. Role of acylethanolamides in the gastrointestinal tract with special reference to food intake and energy balance. narrative or expert review; evidence still limited / 1 linked research note PubMed 19285259
  5. Oleoylethanolamide: A novel pharmaceutical agent in the management of obesity-an updated review. narrative or expert review; evidence still limited / 1 linked research note PubMed 30537148
  6. A fatty gut feeling. narrative or expert review; evidence still limited / 1 linked research note PubMed 23567058
  7. Analgesic properties of oleoylethanolamide (OEA) in visceral and inflammatory pain. animal study; mechanism-focused research / 1 linked research note PubMed 17449181
  8. Regulation of food intake by oleoylethanolamide. narrative or expert review; evidence still limited / 1 linked research note PubMed 15770421
  9. The endocannabinoid and paracannabinoid systems in natural reward processes: possible pharmacological targets? narrative or expert review; evidence still limited / 1 linked research note PubMed 40274041
  10. Brain molecules and appetite: the case of oleoylethanolamide. narrative or expert review; evidence still limited / 1 linked research note PubMed 23464987
  11. The OEA effect on food intake is independent from the presence of PPARα in the intestine and the nodose ganglion, while the impact of OEA on energy expenditure requires the presence of PPARα in mice. animal study; mechanism-focused research / 1 linked research note PubMed 29936173
  12. GPR119 Is a Potent Regulator of Human Sebocyte Biology. cell or laboratory study; mechanism-focused research / 1 linked research note PubMed 32142797
  13. Oea Signaling Pathways and the Metabolic Benefits of Vertical Sleeve Gastrectomy. animal study; mechanism-focused research / 1 linked research note PubMed 30702457
  14. Regulation of Cholesterol and Triglyceride Metabolism by Fatty acid Ethanolamides. narrative or expert review; evidence still limited / 1 linked research note PubMed 42068417
  15. Investigation the effect of oleoylethanolamide supplementation on the abundance of Akkermansia muciniphila bacterium and the dietary intakes in people with obesity: A randomized clinical trial. clinical study in people; evidence still limited / 1 linked research note PubMed 31132422